Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Institutional Ownership : 0.58% (As of Apr. 30, 2024)

View and export this data going back to 2006. Start your Free Trial

What is Cyclacel Pharmaceuticals Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cyclacel Pharmaceuticals's institutional ownership is 0.58%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cyclacel Pharmaceuticals's Insider Ownership is 80.84%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cyclacel Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 94.62%.

Cyclacel Pharmaceuticals Institutional Ownership Historical Data

The historical data trend for Cyclacel Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals Institutional Ownership Chart

Cyclacel Pharmaceuticals Historical Data

The historical data trend for Cyclacel Pharmaceuticals can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	1.26	1.26	1.26	0.95	0.95	0.95	0.73	0.73	0.58	0.58

Cyclacel Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (NAS:CYCC) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

CYCCP.PFD:USA UXI:Germany

Address

200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922

Website

https://www.cyclacel.com

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

Executives

Spiro Rombotis	director, officer: President & C.E.O.	C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Paul Mcbarron	director, officer: E.V.P., Finance & C.O.O.	C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Kenneth M. Ferguson	director	2125 1ST AVENUE #2902, SEATTLE WA 98121-2121
Sam L Barker	director	51 AUNT MOLLY ROAD, HOPEWELL NJ 08525
Brian Schwartz	director	C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Karin L Walker	director	C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Mark Kirschbaum	officer: Chief Medical Officer	66 WEST 38TH STREET, APT. 19D, NEW YORK NY 10018
Robert J. Spiegel	director	C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Eastern Capital Ltd	10 percent owner	10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Kevin C Tang	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Management Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Portfolio Services Ltd.	10 percent owner	10 MARKET STREET, # 773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Kenneth Bryan Dart	10 percent owner	P. O. BOX 31300, GRAND CAYMAN E9 KY1-1206
Lloyd Sems	director	C/O SEMS CAPITAL, 7 DEY STREET, SUITE 1101, NEW YORK NY 10017